ArticleTherapeutic advances in medical oncology2012
Beta-adrenergic blocking drugs in breast cancer: a perspective review.
Article in Therapeutic advances in medical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.Breast cancer research : BCR · 2016Pooled it
- Neural-tumor crosstalk and molecular targeting: mechanisms and therapeutic implications in cancer neuroscience.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.Pharmacology research & perspectives · 2026Article
- Article
- The multifaceted role of beta-blockers in overcoming cancer progression and drug resistance: Extending beyond cardiovascular disorders.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Review
- Beta 2 adrenergic receptor and mu opioid receptor interact to potentiate the aggressiveness of human breast cancer cell by activating the glycogen synthase kinase 3 signaling.Breast cancer research : BCR · 2022Article
- Screening of GPCR drugs for repurposing in breast cancer.Frontiers in pharmacology · 2022Article
- Article
- Article
- Prognostic role of the beta-2 adrenergic receptor in clear cell renal cell carcinoma.Animal cells and systems · 2019Article
- β2ARs stimulation in osteoblasts promotes breast cancer cell adhesion to bone marrow endothelial cells in an IL-1β and selectin-dependent manner.Journal of bone oncology · 2018Article
- Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process.Clinical & experimental metastasis · 2018Review
- Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database.Acta oncologica (Stockholm, Sweden) · 2018Article
- The role of adrenergic receptors in lung cancer.American journal of cancer research · 2018Review
- Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies.Oncotarget · 2017Article
- Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and β2AR-Dependent Neo-Angiogenic Switch.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Article
- Analysis of the correlation among hypertension, the intake of β-blockers, and overall survival outcome in patients undergoing chemoradiotherapy with inoperable stage III non-small cell lung cancer.American journal of cancer research · 2017Article
- The Clinical Relevance of Beta Blockers in Ovarian Carcinoma: A Systematic Review.Geburtshilfe und Frauenheilkunde · 2016Review
- The β2-adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016Article
- Beta Adrenergic Signaling: A Targetable Regulator of Angiosarcoma and Hemangiosarcoma.Veterinary sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and breast cancer progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signalling can inhibit multiple cellular processes involved in breast cancer progression and metastasis, including extracellular matrix invasion, expression of inflammatory and chemotactic cytokines, angiogenesis and tumour immune responses. This has led to the hypothesis that the commonly prescribed class of β-AR antagonist drugs (β-blockers) may favourably impact cancer progression. A number of recent pharmacoepidemiological studies have examined the association between β-blocker exposure and breast cancer progression. The results from these studies have suggested a potential role for targeting the β-AR pathway in breast cancer patients. Larger observational studies are, however, required to confirm these results. Questions regarding the type of β-blocker, predictive biomarkers or tumour characteristics, appropriate treatment paradigms and, most importantly, efficacy must also be answered in randomized clinical studies before β-blockers can be considered a therapeutic option for patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.